Brought to you by 
TiGenix gets exclusive rights to mesenchymal stem cell IP from Mesoblast
19 Dec 2017
Executive Summary
Mesoblast Ltd. granted TiGenix NV exclusive rights to patents surrounding the use of adipose-derived mesenchymal stem cells to treat perianal fistulas.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
TiGenix gets exclusive rights to mesenchymal stem cell IP from Mesoblast
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice